Det primære endepunkt for effektivitet i dette studie, overlevelse i alt (OS), var signifikant længere (log- rank test, p=0, 0058) i det regime, der indeholdt docetaxel sammenlignet med PF (median OS:
The primary efficacy endpoint in this study, overall survival (OS) was significantly longer (log-rank test, p = 0.0058) with the docetaxel-containing regimen compared to PF (median OS: